Amgen Inc. (NASDAQ:AMGN) Declares Quarterly Dividend of $2.38

Amgen Inc. (NASDAQ:AMGN) announced a quarterly dividend on Friday, October 31st. Stockholders of record on Friday, November 21st will be paid a dividend of 2.38 per share by the medical research company on Friday, December 12th. This represents a c) annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, November 21st.

Amgen has increased its dividend by an average of 0.1%annually over the last three years and has increased its dividend annually for the last 14 consecutive years. Amgen has a payout ratio of 44.2% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Amgen to earn $21.39 per share next year, which means the company should continue to be able to cover its $9.52 annual dividend with an expected future payout ratio of 44.5%.

Amgen Trading Up 0.7%

NASDAQ AMGN opened at $343.99 on Wednesday. The firm’s fifty day moving average is $297.43 and its two-hundred day moving average is $291.24. Amgen has a one year low of $253.30 and a one year high of $345.84. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market cap of $185.23 billion, a PE ratio of 28.13, a P/E/G ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company’s revenue was up 12.4% on a year-over-year basis. During the same period last year, the business posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Analysts expect that Amgen will post 20.62 earnings per share for the current year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.